Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 21 -28 of 28 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:

First Published: 12/23/2008


21.		Phase II Randomized Study of Neoadjuvant Capecitabine and Concurrent Radiotherapy With Versus Without Panitumumab in Patients With Advanced K-ras Unmutated Rectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				SWS-SAKK-41/07 SAKK-41/07, EudraCT-2008-006012-38, EU-20894, NCT00814619


22.		Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Active				Over 18				Other				UPCI 06-120 NCT00798655


23.		Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects with Metastatic Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				20040205 NCT00101894


24.		Panitumumab Plus Chemoradiotherapy and Induction Chemotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				Other				05-401 NCT00513383


25.		Panitumumab DDI Irinotecan

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 to 75				Pharmaceutical / Industry				20062010 NCT00563316

Last Modified: 12/24/2008 First Published: 2/6/2008


26.		Phase I Study of Everolimus in Combination With Sequential Fluorouracil (5-FU) and Leucovorin Calcium, Panitumumab, Modified 5-FU, Leucovorin Calcium, and Oxaliplatin (mFOLFOX6), and mFOLFOX6 With Panitumumab in Patients With Refractory Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Biomarker/Laboratory analysis, Treatment				Approved-not yet active				18 and over				NCI				UNC-LCCC-0621 UNC-LCCC-0621, NCT00610948


27.		BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				Over 18				Other				1082 NCT00586443


28.		Panitumumab Pediatric Study

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				1 to 17				Pharmaceutical / Industry				20050252 NCT00658658

Select All on One Page


					< Previous 1 2 3

| | | | | | | |

A Service of the National Cancer Institute